Press release content from PR Newswire. The AP news staff was not involved in its creation.
Research from Analysis Group and IHBDH Furthers Understanding of Hemophilia in China
February 9, 2021 GMT
BOSTON, Feb. 9, 2021 /PRNewswire/ Consultants from Analysis Group, a global leader in health economics and outcomes research (HEOR), and the Institute of Hematology & Blood Diseases Hospital (IHBDH), a clinical and research institute of the Chinese Academy of Medical Sciences and Peking Union Medical College, published a pair of studies in the journal Haemophilia advancing the understanding of hemophilia in China. The study results provide critical information on patient characteristics, treatment strategies, and other clinical information needed to aid regulatory decision making, enhance the quality of care, and improve patient outcomes.
Sanofi delivered close to double-digit Q4 2020 business EPS(1) growth at CER
Specialty Care sales grew 18.3%, driven by strong Dupixent
performance (+54.2% to €982 million).
Vaccines up 14.6%, driven by record demand for differentiated influenza vaccines and continued growth of PPH.
General Medicines declined 7.5%, reflecting lower U.S. Diabetes sales, COVID environment and portfolio streamlining.
CHC down 3.0% due to decreased sales of Cough & Cold related portfolio in Europe partially offset by Digestive Health brands.
Leveraged business EPS as the result of prioritization within R&D and continued execution on smart spending initiatives.
Sales down 2.4% and business EPS flat on a reported basis, as a result of the overall adverse impact from foreign currency rates.
F. Hoffmann-La Roche Ltd: Roche reports solid results in 2020
Group sales increase 1%
1 at constant exchange rates (CER); 5% decline in Swiss francs, as a result of continued appreciation of the Swiss franc against most currencies
Pharmaceuticals Division sales decline 2%; continued strong sales growth of newly launched medicines (+32%
2, including Tecentriq, Hemlibra, Ocrevus, Perjeta and Kadcyla) largely offsets the impact of competition from biosimilars (CHF -5.1 billion at CER
3), but not the additional COVID-19-related impact from missed medical appointments
Diagnostics Division sales grow 14% for the full year (+28% in the fourth quarter) due to COVID-19 diagnostics; more than offsetting a decline in routine testing due to COVID-19
Shanghai Junshi Biosciences : Eucure Biopharma Announces Encouraging Antitumor Activity of Its anti-CD40 Antibody in PD-1 Refractory Ocular Melanoma when Combined with Junshi Biosciences Toripalimab marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
BOSTON and BEIJING, Feb. 3, 2021 /PRNewswire/ Eucure Biopharma, a biopharmaceutical company dedicated to developing immuno-oncology antibody drugs, announced that its investigational anti-CD40 antibody drug (YH003), when combined with Junshi Biosciences anti-PD-1 antibody Toripalimab (TUOYI
®), demonstrated encouraging anti-tumor activity in an ongoing Phase I/II clinical trial in Australia. The trial is a multicenter, open label study, with an initial multiple-dose-escalation phase designed to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of YH003 in combination with Toripalimab in subjects with advanced solid tumors. The second phase is a cohort extension phase to assess the safety and preliminary efficacy of YH003/Toripalimab with or without chemotherapy in PD-1 refractory, advanced unresectable/metastatic melanoma and pancreatic ductal adenocarcinoma.